Improved growth during the first year of monthly intravenous pamidronate therapy in prepubertal patients with osteogenesis imperfecta

被引：0
|
作者：
Heino, Terhi J. [1 ,2 ,3 ]
Astrom, Eva [1 ,2 ]
Savendahl, Lars [1 ,2 ]
Soderhall, Stefan [1 ,2 ]
机构：
[1] Karolinska Univ Hosp, Karolinska Inst, Dept Women & Child Hlth, Stockholm, Sweden
[2] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden
[3] Univ Turku, Orthopaed Res Unit, Turku, Finland
来源：
HORMONE RESEARCH | 2009年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：223 / 223
页数：1
相关论文
共 50 条
  • [21] Osteogenesis imperfecta: Anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy
    Vallo, A
    Rodriguez-Leyva, F
    Soriano, JR
    ACTA PAEDIATRICA, 2006, 95 (03) : 332 - 339
  • [22] Osteogenesis imperfecta: Continuous increment of bone mass with cyclical intravenous pamidronate following oral therapy.
    Tau, C
    Mautelen, C
    Brunetto, O
    Alvarez, V
    Rubinstein, M
    BONE, 2002, 30 (06) : 942 - 942
  • [23] Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy
    Arikoski, P
    Silverwood, B
    Tillmann, V
    Bishop, NJ
    BONE, 2004, 34 (03) : 539 - 546
  • [24] Decrease in serum FGF23 levels after intravenous infusion of pamidronate in patients with osteogenesis imperfecta
    Kitaoka, Taichi
    Namba, Noriyuki
    Miura, Kohji
    Kubota, Takuo
    Ohata, Yasuhisa
    Fujiwara, Makoto
    Hirai, Haruhiko
    Yamamoto, Takehisa
    Ozono, Keiichi
    JOURNAL OF BONE AND MINERAL METABOLISM, 2011, 29 (05) : 598 - 605
  • [25] Decrease in serum FGF23 levels after intravenous infusion of pamidronate in patients with osteogenesis imperfecta
    Taichi Kitaoka
    Noriyuki Namba
    Kohji Miura
    Takuo Kubota
    Yasuhisa Ohata
    Makoto Fujiwara
    Haruhiko Hirai
    Takehisa Yamamoto
    Keiichi Ozono
    Journal of Bone and Mineral Metabolism, 2011, 29 : 598 - 605
  • [26] Intravenous administration of pamidronate decreases serum levels of FGF23 rapidly in patients with osteogenesis imperfecta
    Kitaoka, T.
    Namb, N.
    Miura, K.
    Kubota, T.
    Hirai, H.
    Nakajima, S.
    Yamamoto, T.
    Ozono, K.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S222 - S222
  • [27] Osteogenesis imperfecta: continuous increment of bone mass with two years of cyclical intravenous pamidronate following oral therapy
    Tau, C
    Mautalen, C
    Brunetto, O
    Alvarez, V
    Farenga, M
    Rubinstein, M
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S370 - S370
  • [28] Bone Changes During Growth in Patients with Osteogenesis Imperfecta
    Burgueno-Torres, Laura
    Garcia-Boedo, Lara
    de Nova-Garcia, Manuel Joaquin
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (05)
  • [29] Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV
    Zeitlin, L
    Rauch, F
    Plotkin, H
    Glorieux, FH
    PEDIATRICS, 2003, 111 (05) : 1030 - 1036
  • [30] Unusual Femur Stress Fractures in Children With Osteogenesis Imperfecta and Intramedullary Rods on Long-term Intravenous Pamidronate Therapy
    Hegazy, Abdelsalam
    Kenawey, Mohamed
    Sochett, Etienne
    Tile, Lianne
    Cheung, Angela M.
    Howard, Andrew W.
    JOURNAL OF PEDIATRIC ORTHOPAEDICS, 2016, 36 (07) : 757 - 761
12345